A research team from The Second Qilu Hospital of Shandong University described a microfluidic method to boost CAR T cell transduction under low viral doses. The approach aims to shorten the manufacturing timeline for CD19-targeting CAR-T cells while improving process efficiency, addressing a key bottleneck for scaling personalized cell therapies.